|India Globalization Capital, Inc. (NYSE: IGC) Could Release Potential Blockbuster Alzheimer’s Treatment in Early 2018|
- On the verge of releasing potential Cannabis-based blockbuster Alzheimer’s treatment
- Company is able to hugely accelerate release of this treatment in recreational cannabis states
- Market potential for drugs to treat and prevent Alzheimer’s is in the billions of dollars
According to information from the Alzheimer’s Association, approximately 47 million people are living with dementia throughout the world—a figure that has been projected to rise to 76 million by 2030. There is still no cure for this devastating disease. However, India Globalization Capital, Inc. (NYSE MKT: IGC) is on the precipice of bringing a potential blockbuster treatment for Alzheimer’s to the market—an event that could happen by early 2018.
Recently, IGC announced it is readying a line of cannabis-based products targeting Alzheimer’s disease based on novel data (http://nnw.fm/l2NJw). The company has been engineering genetic cell lines that show the protein Aβ decreases by as much as 40 percent at various concentrations of tetrahydrocannabinol (THC) without neuron damage. (Amyloid beta peptides, or Aβ plaque, buildup in the brain is believed to be the chief cause of Alzheimer’s). This compelling in vitro data shows tremendous promise for treating and even preventing Alzheimer’s.
“As Alzheimer’s progresses, synaptic dysfunction and the death of neurons lead to memory loss. These study results, when combined with the earlier reported data that shows IGC-AD1 reduces Aβ40 and Aβ42 production by as much as 50%, and 40%, without any toxicity, represent a highly significant novel breakthrough that could potentially bring much needed relief from this devastating disease,” IGC CEO Ram Mukunda said, as quoted in the press release.
IGC currently has four products in its pipeline: Hyalolex, which is the company’s breakthrough treatment aimed at reducing beta-amyloid building up in Alzheimer’s patients; Natrinol, or synthetic THC, which has application for relieving nausea, vomiting and loss of appetite in patients with AIDS and cancer; Caesafin, which uses combination therapy to assuage seizures in dogs and cats; and Serosapse, which addresses various endpoints in Parkinson’s disease.
Typically, pharmaceutical companies are only able to market a product once it has received FDA approval, which involves a very lengthy and expensive process. Because IGC is using a combination therapy, the company is able to bring products to market significantly faster and at a substantially lower cost. IGC is actually able to bring some of its products to market in a matter of months rather than years by bringing them to cannabis medical dispensaries. The company’s breakthrough Alzheimer’s treatment is one such product.
This hugely accelerated introduction of Hyalolex can only be accomplished in states where medical cannabis is legal and where the ailment (in this case Alzheimer’s) is an approved medical condition. In states where recreational cannabis has been approved, IGC doesn’t have to contend with whether or not Alzheimer’s is an approved medical condition in order to bring its treatment to market. Therefore, these states (recreational marijuana states like California, Colorado, Oregon, etc.) will be targeted first with IGC’s cannabis-based Alzheimer’s treatment.
In view of IGC’s pipeline, consisting of Hyalolex for the treatment of Alzheimer’s and other phytocannabinoid-based therapies, the company’s market valuation is poised to explode. Investors have made Alzheimer’s treatment drugs a high priority in the biotechnology field, and the market potential for a preventative Alzheimer’s treatment is in the billions of dollars. Some of IGC’s Alzheimer’s-focused competitors already have market valuations in the hundreds of millions or billions of dollars—making the sky the limit for IGC’s future growth.
For more information, visit the company’s website at www.IGCInc.us
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer